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Abstract 
The objective of this study was to develop a biomimetic, highly porous collagen-
hydroxyapatite composite scaffold for bone tissue engineering, combining the 
biological performance and the high porosity of a collagen scaffold with the high 
mechanical stiffness of a hydroxyapatite scaffold. 
Pure collagen scaffolds were produced in a lyophilisation process as previously 
described. The collagen scaffolds were immersed in simulated body fluid (SBF) 
to provide a biomimetic coating. Pure collagen scaffolds served as a control. The 
mechanical, material, and structural properties of the scaffolds were analysed 
and the biological performance of the scaffolds was evaluated by monitoring the 
cellular metabolic activity and cell number at 1, 2 and 7 days post seeding. 
The SBF- treated scaffolds showed a significantly increased stiffness compared 
to the pure collagen group (4-fold increase). While the porosity of the scaffolds 
was reduced, the scaffolds still retained a highly interconnected structure with a 
porosity as high as 95%. FT-IR indicated that the SBF coating exhibited similar 
characterisitcs to pure hydroxyapatite while the excellent biological performance 
of the collagen scaffolds was maintained in the collagen-hydroxyapatite scaffolds 
as demonstrated from cellular metabolic activity and total cell number. 
This investigation has successfully developed a biomimetic collagen-
hydroxyapatite composite scaffold. An increase in the mechanical properties 
combined with an excellent biological performance in vitro was observed, 
indicating the high potential of the scaffold for bone tissue engineering. 
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Introduction 
The annual worldwide market for bone grafts or bone graft substitutes is 
approaching $US 1 billion, with up to 4 million bone replacement procedures. 
This makes bone second only to blood transfusions on the list of transplanted 
materials (American Association of Orthopaedic Surgeons Report 2002). The 
most common graft is an autograft, whereby bone is taken from the patient‘s own 
body and re-implanted. However, there is a limited amount of bone which can be 
removed from a particular donor site and additional invasive surgery is necessary 
which can be associated with donor site morbidity. An alternative treatment is the 
use of an allograft whereby bone is removed from an organ donor. The 
drawbacks with this approach include a risk of infectious disease being 
transmitted and a shortage of available donors. Therefore, bone graft research 
has begun to focus on bone tissue engineering (TE) and novel bone graft 
substitutes. 
 
Collagen makes up to 89% of the organic matrix and 32% of the volumetric 
composition of bone 1. Collagen scaffolds produced according to a standardised 
protocol 2,3 show an excellent biological performance due to their high porosity 
and permeability. Previous investigations in our laboratory indicated that 
scaffolds require a high porosity and surface area 2, combined with a good 
permeability and pore interconnectivity 4, for cell migration and nutrient perfusion 
during the cell culturing process. The main disadvantage of collagen as a 
scaffold material for bone tissue engineering is that it has relatively poor 
mechanical properties. 
 
In bone tissue engineering, much interest has focused on using synthetic 
polymers or pure ceramic materials for scaffold fabrication. These materials tend 
to have better mechanical properties than collagen scaffolds; however, other 
disadvantages appear while using these scaffolds. Many synthetic polymers 
demonstrate hydrophobic behaviour. Hydrophobic surfaces show a lower 
proliferative and a higher apoptotic rate for osteogenic cells 5-7. In addition, 
polymeric  biomaterials have bioinert surfaces that lack bioactive functions for 
bone formation 7. Upon implantation, fibrous tissue often encapsulates these 
bone substitutes. Recent investigations have focused on chemically coating 
various scaffold types with calcium-phosphate (CP) or hydroxyapatite (HA) using 
different immersing techniques to improve their material properties 8-12. Bone-like 
apatite layers on the surface of bone grafts improve their ability to create a bond 
with the living host bone and enhance osteoconductivity 7. In particular, simulated 
body fluid (SBF), an acellular solution developed in 1990 by Kokubo et al. 13 with 
an ion concentration similar to that of human extracellular fluids has been used to 
precipitate HA or CP on scaffolds 7,11,14. SBF is a metastable solution containing 
calcium and phosphate ions supersaturated with respect to the apatite 13 and can 
be used to coat various materials with apatite under biomimetic conditions. 
Different SBF treatments have been investigated to form CP layers to improve 
surfaces for better bioactivity and osteointegration on titanium alloys 15,16, 
polymers 9,10,17 and composite biomaterials 7. 
 
Scaffolds for tissue engineering require a highly porous structure and an 
excellent biocompatibility as commonly exhibited by collagen scaffolds. However, 
scaffolds for bone tissue engineering require good mechanical properties to 
facilitate load-bearing after implantation, a characteristic common to ceramic 
scaffolds but not found in biological scaffolds. The goal of this study was 
therefore, to develop a novel collagen-hydroxyapatite composite scaffold which 
combined the advantageous properties of both materials by using a SBF coating 
treatment on a highly porous collagen scaffold. The specific goals of the study 
were to develop a collagen-hydroxyapatite composite scaffold using a SBF 
treatment to (i) improve the mechanical properties of the composite scaffolds 
relative to pure collagen scaffolds and (ii) to maintain the high porosity and the 
high biological performance of the pure collagen scaffolds in the new variants. 
 
Methods 
 
Fabrication of scaffolds 
 
Pure collagen scaffolds were fabricated using a standardised protocol 2-4. Briefly, 
a collagen suspension was produced from microfibrillar type I collagen, isolated 
from bovine tendon (Integra Life Sciences, Inc., Plainsboro, NJ, USA) and 0.05 M 
acetic acid by mixing at 15,000 rpm in an overhead blender (IKA Works, Inc., 
Wilmington, NC, USA). The slurry was poured into a stainless steel tray which 
was placed into a freeze-dryer (VirTis Co., Gardiner, NY, USA). The temperature 
was then lowered at a constant cooling rate of 1º C/min to the final temperature. 
A final freeze-drying temperature of -40ºC was used to produce scaffolds with a 
mean pore size of approximately 95 µm [3]. The shelf and chamber temperature 
were then held constant at the final temperature for 60 minutes to complete the 
freezing process. The shelf temperature was then ramped up to 0ºC for 160 
minutes. The ice phase was then sublimated under a vacuum of approximately 
200 mTorr at 0ºC for 17 hours to produce the porous collagen scaffold. Samples 
with a diameter of 9.5 mm and a height of 4 mm were cut out for further 
experiments using a punch. 
 
Simulated body fluid (SBF) was prepared by dissolving reagent-grade chemicals 
NaCl, MgCl2, CaCl2, Na2HPO4 and NaHCO3 (Sigma Aldrich, Germany) into 
demineralized water according to Kokubo et al 7,13. A SBF solution with a 
concentration of five times the ion concentration of human plasma was made up 
to restore a pH value of 7.4 7,13. Pure collagen scaffolds (n=6) were then 
immersed into the solution. Each scaffold was immersed in 3ml of the SBF 
solution for 4 days with daily replenishment of the solution. During this time 
period calcium and phosphate should deposit on the collagen scaffolds to form a 
HA layer on the collagen struts. This treatment was performed at 37°C in an 
incubator. 
 
Characterisation of scaffolds 
 
Fourier transform infrared (FT-IR) spectra measurements were performed to 
investigate the material properties of the scaffolds. In order to evaluate the typical 
collagen and HA characteristics, FT-IR spectra were made in extinction using a 
controlled potassium bromide (KBr) embedding technique in the range from 400 
to 4000 cm-1 at a resolution of 4 cm-1 (Bruker Tensor 27, Nicolet Instruments, 
USA). 300 mg of dried KBr powder and approximately 1 mg of pulverized 
collagen-hydroxyapatite samples were mixed and ground using an agate mortar 
and pestle. 
 
Mechanical characterisation of the scaffolds (n=6) was performed on a uniaxial 
testing system (Zwick Z005 with a 5 N load cell). Compression tests were 
performed at room temperature in phosphate buffered saline (PBS). The slope of 
the plot of the stress strain curve was determined between strains of 2 and 5%, 
resulting in a Young’s Modulus value for each scaffold. 
 
The scaffolds were weighed before and after SBF treatment using a digital scale 
(Mettler Toledo, PB 153-S, Switzerland; accuracy of 0.1 mg). The individual 
dimensions of the scaffolds were measured using a digital camera and the image 
editing software ImageJ. The weight of the composite scaffolds was then 
compared to the weight of the pure collagen scaffolds to find the percentage of 
collagen and hydroxxyapatite in the scaffolds (Equation 1 and 2). The density 
was calculated using the weight and volume of each individual scaffold (equation 
3). 
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The collagen/HA ratio was calculated using the percentage of collagen and HA 
the scaffold and the densities of pure collagen (1.343 g/cm2) 18 and the density of 
HA (3.14 g/cm2) (Equation 4). 
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The relative density of the scaffolds was then calculated using the collagen/ HA 
ratio of each scaffold (Equation 5). The individual porosities of the scaffolds were 
calculated using equation 6 19. 
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Biological performance of scaffolds 
 
12.7 mm diameter scaffold samples of pure collagen (control group) and the SBF 
treated collagen scaffolds were seeded with 1.5 million MC3T3-E1 mouse pre-
osteoblast cells. 100 µL of cell suspension was seeded drop-wise onto each 
scaffold side using an established technique [3]. The scaffolds were kept in alpha 
minimum essential medium supplemented with 2% penicillin/streptomycin, 1% L-
glutamine and 10% foetal bovine serum in an incubator at 37°C and 5% CO2 for 
up to 7 days. Metabolic activity and cell number were monitored at 1, 2 and 7 
days post-seeding.  
 
Metabolic activity was measured using a non-destructive colourimetric assay 
(alamarBlue®). The scaffolds were incubated with a 10% solution of 
alamarBlue® for 2 hours on an orbital shaker in an incubator. Three 100 µL 
samples of the medium/ alamarBlue® solution were taken from each scaffold and 
analysed regarding the absorbance of the supernatant at 540nm and 620nm was 
on a spectrometer (Titertek, Germany). The percentage reduction of the blue dye 
to the reduced pink form which represents the metabolic activity of the cells is 
obtained using: 
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where 540A  is the absorbance of the sample at 540nm, 620A  is the absorbance at 
620nm. blueA  is the absorbance of a control sample of 10% solution of 
alamarBlue®, not incubated with a cell-seeded scaffold and mediumA  is the 
absorbance of a sample of culture medium. 
 
Cell number was quantified using a DNA assay (Hoechst 33258). This is a 
fluorescent dye that bonds to double stranded DNA. Scaffolds were digested in 
papain (Sigma-Aldrich, Germany) in a water bath at 60°C over 6 hours. 30 µL of 
the digested scaffolds were mixed with 600 µL of a working dye solution made up 
of Tris, Na2EDTA, NaCl, distilled water and the Hoechst 33258 dye solution 
(Sigma-Aldrich, Germany). The fluorescence of the samples was measured at 
460nm after excitation at 355nm in a multilabel counter (Wallac Victor2™ 1420, 
Perkin Elmer Life Sciences, Finland). Fluorescence readings were compared to a 
standard curve to give cell number. 
 
Statistical analysis 
Statistical analysis was performed in SPSS using a 2-tailed student-T test for 2 
variables or a one-way ANOVA with the Tukey PostHoc test for more than 2 
variables. The level for significance was set as p < 0.05. 
Results 
 
Figure 1 shows the effect of SBF treatment using FT-IR. The spectra of the SBF 
treated scaffolds were analysed and compared to the spectra of pure untreated 
collagen scaffolds and HA powder (Plasma Biotal Limited, North Derbyshire UK). 
HA powder shows distinctive peaks in the region of 500 - 600 cm-1 and at 1080 
cm-1. Pure collagen scaffolds show peaks at 1600 cm-1 and 3400 cm-1. The SBF 
treated scaffolds possess the typical HA (500 - 600 cm-1 and 1080 cm-1) and 
collagen peaks (1600 cm-1 and 3400 cm-1) indicating the presence of a collagen 
and hydroxyapatite phase in the scaffolds. 
 
Figure 2 shows the effect of SBF treatment on the mechanical properties of the 
scaffolds, with pure collagen scaffolds serving as control. The compressive 
moduli were determined from stress-strain curves. Pure collagen scaffolds 
demonstrated a mean compressive modulus of 0.23 kPa. The treated scaffolds 
demonstrated a mean modulus of 0.9 kPa which was significantly higher (p < 
0.005) than the control group. 
 
Figure 3 shows the effect of SBF treatment on the porosity of the scaffolds. The 
SBF treated scaffolds show a significantly (p<0.01) decreased porosity compared 
to the pure collagen scaffolds. However, while pure collagen scaffolds have a 
porosity of 99.5%, the SBF treated scaffolds still show a porosity as high as 
94.9%. 
 Figure 4 shows the effect of SBF treatment on the metabolic activity of cells 
seeded on the scaffolds at 1, 2 and 7 days post seeding. A non-significant 
increase in metabolic activity over cell culture time was seen from 1 to 7 days for 
both scaffold types. No statistical difference was found in metabolic activity 
between pure collagen scaffolds and SBF treated scaffolds. 
 
Figure 5 shows the effect of SBF treatment on the cell number in the scaffolds at 
1, 2 and 7 days post seeding. No statistical difference was found comparing the 
SBF- treated scaffolds with the pure collagen scaffolds, although the SBF treated 
scaffolds showed a non-significant increase after 7 days post seeding compared 
to the collagen scaffolds (p = 0.112). The pure collagen scaffolds showed similar 
cell numbers from 1 to 7 days post seeding. However the SBF treated scaffolds 
showed an increase from day 1 to day 7 post seeding (p < 0.15) demonstrating 
that the composite scaffolds support cell proliferation. 
Discussion 
Pure collagen and pure hydroxyapatite scaffolds have been commonly used in 
tissue engineering to date 3,20-25. While collagen scaffolds show excellent 
biological performance 2-4,26, they do not possess adequate mechanical 
properties on their own 24 which limits their potential use for bone tissue 
engineering. On the other hand hydroxyapatite scaffolds show excellent 
mechanical properties 27. However, many investigations have demonstrated that 
the brittle behaviour and low-degradibility limits the use of pure hydroxyapatite 
scaffolds in tissue engineering 20-22,28. In this investigation a novel collagen-
hydroxyapatite composite scaffold has been successfully developed by 
immersing a collagen scaffold in simulated body fluid. The new scaffolds indicate 
a 4-fold increase in stiffness compared to the control pure collagen scaffolds. 
Although the porosity was decreased, the porosity remains as high as 95% and 
the biological performance analysed by cell number and metabolic activity 
showed promising results in vitro. 
 
Adequate mechanical properties are essential in bone TE, not only for implanting 
cell-scaffold constructs into load-bearing areas, but also for improving their 
handling attributes during surgery. In this investigation the mechanical properties 
of pure collagen scaffolds have been improved significantly. Despite this 
increased stiffness from 230 Pa to almost 900 Pa, the construct does not exhibit 
the mechanical properties necessary for implantation into load bearing defects 
without external fixation. However, the handling properties of the scaffolds have 
been significantly improved which expands their use for surgical application. 
Furthermore, from a bone tissue engineering perspective, mineralisation of the 
scaffolds following extra cellular matrix deposition by osteoblasts would lead to a 
further increase in the mechanical properties. The novel collagen-hydroxyapatite 
scaffolds show sufficient mechanical properties for maxillofacial, cranial or other 
non-load bearing bone defects and the improved mechanical properties may 
facilitiate increased cellular penetration to the centre of the scaffolds by helping 
to maintain the interconnected pore structure of the scaffolds during hydration. 
 
The permeability of scaffolds used for tissue engineering is very important as it 
controls the rate of cell migration, as well as the diffusion of nutrients and waste 
products in and out of the scaffold 29,30. The permeability of scaffolds is related to 
porosity, pore size and the interconnectivity/distribution of the pores 31. 
Lyophilised collagen scaffolds developed by Yannas et al. and optimised by 
O’Brien et al. show a homogenous pore structure and a mean pore size that can 
be controlled to vary between 70 µm to 150 µm 2,23. In this investigation pure 
collagen scaffolds produced at a final freezing temperature of -40 ºC have been 
used to obtain a mean pore size of approximately 95 µm and a porosity of 99.5%. 
Similar scaffolds showed promising results in cell adhesion of MC3T3-E1 mouse 
clonal osteogenic cells 2 and permeability 4. The SBF immersion treatment 
generates a HA layer of only a few micrometers thick which does not affect the 
interconnected pore structure or alter the mean pore size of the scaffolds 11. 
 
In this investigation, the porosity of the SBF- treated scaffolds was seen to 
decrease compared to the original pure collagen scaffolds which have a porosity 
of 99.5%. However, the collagen-hydroxyapatite scaffolds retained a porosity of 
95% after the immersion in SBF which is still a highly porous construct compared 
to many other scaffold types intended for use in bone tissue engineering which 
typically have porosities ranging from 40-70% 28,32,33. In particular, in comparison 
with dense sintered ceramic scaffolds made from CP or HA, the high porosity 
collagen-hydroxyapatite composite scaffolds have an enormous potential for 
bone TE or bone repair. 
 
FT-IR spectra of the SBF treated scaffolds show the presence of HA on the SBF 
treated scaffolds (Figure 3). Compared to the control group (pure collagen), 
distinctive peaks between the wavenumbers 560–660 cm-1 can be seen. These 
peaks exhibit similar characterisitcs to HA powder 34. The peak at 600cm-1 
represents calcium crystal formation 34. A second peak at 1030cm-1 with a 
shoulder peak at 1045cm-1 also indicates a similarity to the HA powder peaks. 
This peak seen in the spectra of the treated scaffold represents orthophosphate 
(PO43-) formation in the scaffold 34. Both peaks show the presence of HA in the 
scaffolds after treatment with SBF. The shape of the peaks between 500cm-1 and 
600cm-1 with some distinctive peaks on a broad curve indicates the presence of 
crystalline HA, and amorphous CP. The peaks at 1630cm-1 and 3410cm-1 with 
their similarities to the collagen scaffold spectra indicate the presence of collagen 
after the treatments. 
The novel developed biomimetic collagen-hydroxyapatite scaffolds showed an 
excellent biocompatibility and bioactivity in vitro using assays to analyse the cell 
number (Hoechst 33258) and metabolic activity (alamarBlue®). An increase in 
mean cell number per scaffold was observed on the composite collagen-
hydroxyapatite scaffolds after 7 days. No statistical difference in the biological 
performance could be seen between collagen-hydroxyapatite scaffolds and pure 
collagen scaffolds. Analysing the metabolic activity of the cells supported these 
findings, indicating an increase in metabolic activity at seven days compared to 
the first day. This trend was not significant due to high deviations but is 
nonetheless a very promising result as it suggest that the composite scaffolds 
support cell proliferation. Pure collagen scaffolds are known to exhibit excellent 
biological performance and to support cell adhesion, growth and proliferation 
3,25,35
. Statistical analyses showed no significant differences between the pure 
collagen scaffolds and the collagen-hydroxyapatite scaffolds, indicating the same 
excellent biological performance as pure collagen scaffolds in the new 
constructs. 
Taken together, these cell culture experiments indicate cellular proliferation on 
composite scaffolds over a 7 day period. This is the first step in the development 
of bone tissue: proliferation occurs for the first 10-12 days of culture, followed by 
ECM synthesis and maturation and finally mineralisation 36. The composite 
scaffolds support this initial step which is promising. Longer culture periods using 
osteogenic medium are needed to ascertain whether or not the scaffolds support 
further development of bone tissue. 
Conclusion 
 
This investigation has successfully developed a biomimetic collagen-
hydroxyapatite composite scaffold using a SBF immersing technique. This novel 
collagen-hydroxyapatite scaffold demonstrates increased stiffness compared to 
pure collagen scaffolds while still retaining a highly porous structure (95% pore 
volume). These results, combined with the promising biological performance of 
the scaffold demonstrate its potential for bone tissue engineering. 
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 Figure 1: FT-IR Spectra of HA powder, pure collagen scaffolds and SBF treated 
collagen scaffolds (n=6). 
 Figure 2 Compressive moduli of the collagen scaffold and the SBF treated 
scaffolds (n=9). 
 Figure 3: Porosity of the collagen scaffold and the SBF treated scaffolds (n=6). 
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Figure 4: Metabolic activity of SBF treated collagen scaffolds and pure collagen 
scaffolds at 1, 2 and 7 days post seeding (n=9). 
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Figure 5: Cell number of SBF treated collagen scaffolds and pure collagen 
scaffolds at 1, 2 and 7 days post seeding (n=9). 
 
